A Phase 1b Study of QX1206 in T2DM Patients With NAFLD

Inclusion Criteria: * Signed written informed consent must be obtained and documented * 18 years of age and \< 65 years old * BMI ≥ 18 kg/m\^2 and \< 45 kg/m\^2 * T2DM diagnosed per 2021 American Diabetes Association criteria * Diagnosis of NAFLD * For male or female patients of child producing potential: must agree to use contraception or take measures to avoid pregnancy during the study * Women of child-bearing potential (WOCBP) must have a negative pregnancy test * Serum creatinine \< 1.5×ULN or creatinine clearance ≥ 60 ml/min * Participating patients must be able to comply with all study requirements and the study center must have appropriate means of ensuring protocol compliance for each participating patient Exclusion Criteria: * Uncontrolled diabetes * Patients with an active, serious medical disease that limit activities of daily living * Patients with current, significant alcohol consumption or a history of significant alcohol consumption * Patients with any of the following clinical laboratory abnormalities at screen and confirmed by a single repeat if deemed necessary: * Fasting triglycerides \> 500 mg/dL * Fasting direct LDL-C \> 190 mg/dL * AST \> 5.0 × upper limit of normal (ULN) * ALT \> 5.0 × ULN * Alkaline phosphatase (ALP) ≥ 2 × ULN * HbA1c \> 10.5% * Fasting plasma glucose (FPG) \> 240 mg/dL (13.3 mmol/L) * Platelets count \< 140,000/mm\^3 * Patient takes drugs historically associated with NAFLD and other known hepatotoxins * Treatment with drugs (e.g., vitamin E \> 400 IU/day) or herbal supplements with potential anti-NAFLD effect